- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Vivesto AB: Vivesto reports positive Paccal Vet cat topline results supporting continued clinical development | 498 | GlobeNewswire (Europe) | Solna, Sweden, 17, 2026 - Vivesto AB, an oncology-focused development company, today announced positive topline results from its Paccal Vet dose-finding study in cats with solid tumors. The study demonstrates... ► Artikel lesen | |
| VIVESTO Aktie jetzt für 0€ handeln | |||||
| 15.09. | Vivesto AB: Vivesto's positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet | 266 | GlobeNewswire (Europe) | Solna, Sweden, September 15, 2026 - Vivesto AB, an oncology-focused development company, today announced positive topline results from its open label clinical pilot study evaluating Paccal Vet in dogs... ► Artikel lesen | |
| 13.08. | Vivesto AB Q2 Loss Declines | 3 | RTTNews | ||
| 01.07. | Vivesto AB: Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose | 307 | GlobeNewswire (Europe) | Solna, Sweden, July 1, 2026 - Vivesto AB, an oncology-focused development company, today announced that recruitment has been completed in the company's ongoing Paccal Vet dose-finding study in cats... ► Artikel lesen | |
| 26.06. | Vivesto AB: Vivesto completes recruitment in Paccal Vet dog pilot study - topline results expected Q3 2026 | 435 | GlobeNewswire (Europe) | Solna, Sweden, June 26, 2026 - Vivesto AB, an oncology-focused development company, today announced the completion of recruitment in its clinical Paccal Vet pilot study in dogs with splenic hemangiosarcoma... ► Artikel lesen | |
| 16.06. | Vivesto AB: Vivesto reports positive results from i.v. Cantrixil PK/toxicology study | 247 | GlobeNewswire (Europe) | Solna, Sweden, June 16, 2026 - Vivesto AB, an oncology-focused development company, today reports positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The... ► Artikel lesen | |
| 05.06. | Vivesto AB: Vivesto appoints Björn Svanström as CFO | 293 | GlobeNewswire (Europe) | Solna, Sweden, June 5, 2026 - Vivesto AB, an oncology-focused development company, today announces that Björn Svanström was appointed as the new Chief Financial Officer (CFO). Björn Svanström will take... ► Artikel lesen | |
| 20.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 20.05.2026 | 1.032 | Xetra Newsboard | The following instruments on XETRA do have their first trading 20.05.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.05.2026
Aktien
1 CH1107979838 R&S Group Holding AG
2... ► Artikel lesen | |
| 19.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.05.2026 | 805 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 19.05.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.05.2026ISIN NameIE000YUAPTQ0 KRELVEFUMOSCR... ► Artikel lesen | |
| 19.05. | XFRA ISIN CHANGE | 508 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenSE0000722365 Vivesto AB 19.05.2026 SE0028925701 Vivesto AB 20.05.2026 Tausch 100:1NO0013178616 Public Property Invest... ► Artikel lesen | |
| 19.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 19.05.2026 | 536 | Xetra Newsboard | Das Instrument 74I CA13536V1076 CANADIAN BANC CORP CL.A EQUITY wird ex Kapitalmassnahme gehandelt am 19.05.2026 The instrument 74I CA13536V1076 CANADIAN BANC CORP CL.A EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 15.05. | Split and Change of ISIN for Vivesto AB | 616 | GlobeNewswire | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from May 20, 2026. The order book will not change.
... ► Artikel lesen | |
| 13.05. | Vivesto AB: Vivesto announces timetable for reverse share split | 298 | GlobeNewswire (Europe) | At the Annual General Meeting in Vivesto AB ("Vivesto" or the "Company") on 7 May 2026, it was resolved to carry out a reverse share split of 1:100, entailing that one hundred (100) shares are consolidated... ► Artikel lesen | |
| 07.05. | Vivesto AB: Report from Annual General Meeting in Vivesto AB | 381 | GlobeNewswire (Europe) | At the Annual General Meeting in Vivesto AB ("Vivesto" or the "company") held on 7 May 2026, the following resolutions were passed. All resolutions were in accordance with the proposals, described in... ► Artikel lesen | |
| 01.04. | Vivesto AB: The Board of Directors of Vivesto proposes a reverse share split and reduction of the share capital | 224 | GlobeNewswire (Europe) | The Board of Directors of Vivesto AB ("Vivesto" or the "Company") has resolved to propose that the Annual General Meeting on 7 May 2026 resolves on a reverse share split, whereby one hundred (100) existing... ► Artikel lesen | |
| 13.03. | Vivesto AB: First dogs dosed in Vivesto's PK/toxicology study with Cantrixil | 426 | GlobeNewswire (Europe) | Solna, Sweden, March 13, 2026 - Vivesto AB, an oncology-focused development company, today announces that the first dogs have been dosed in the company's ongoing pharmacokinetic (PK) and toxicology... ► Artikel lesen | |
| 27.02. | The observation status for Vivesto AB is removed | 310 | GlobeNewswire | On November 20, 2025, the shares in Vivesto AB (the "Company") were given observation status with reference to uncertainty in respect of the issuer's financial position.
Today, February 27,... ► Artikel lesen | |
| 23.01. | Vivesto AB: Vivesto announces outcome of the rights issue | 360 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 02.01. | Vivesto AB: Vivesto publishes information document regarding the rights issue | 469 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| 31.12.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | 1.610 | Xetra Newsboard | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,150 | -0,14 % | Buy or Goodbye?: Tesla, Totalenergies, Nestle und Bayer - Die Analystenstimmen des Tages | © Foto: Ding Ting/XinHua/dpaTesla, Totalenergies, Nestle und Bayer: Die wichtigsten Analysten-Updates im Überblick Enthaltene Werte: DE000BAY0017,FR0000120271,CH0038863350,US88160R1014Den vollständigen... ► Artikel lesen | |
| NOVO NORDISK | 35,210 | +0,18 % | Novo Nordisk muss zittern: Eli Lilly vor Milliardenchance: Neue Abnehmpille nimmt wichtige EU-Hürde! | Eli Lillys Abnehmpille Foundayo nimmt eine wichtige EU-Hürde. Die mögliche Zulassung verschärft den Milliardenwettbewerb mit Novo Nordisk Enthaltene Werte: US5324571083,DK0062498333Den vollständigen... ► Artikel lesen | |
| MERCK KGAA | 143,75 | -1,78 % | Milliarden-Hammer: Merck geht aufs Ganze: Dieser Milliarden-Deal könnte alles verändern! | © Foto: Arne Dedert/dpaMerck übernimmt Silence Therapeutics für 1,3 Milliarden US-Dollar. Mit innovativer Gen-Technologie will der Pharmakonzern neue Wachstumsfelder erschließen Enthaltene Werte: DE0006599905Den... ► Artikel lesen | |
| GILEAD SCIENCES | 138,58 | -1,13 % | BioNTech SE: BioNTech treibt klinische Phase-3-Studie zu Pumitamig mit Gileads gegen TROP2-gerichtetem Antikörper-Wirkstoff-Konjugat Sacituzumab Govitecan bei Dreifach-Negativem Brustkrebs voran | BioNTech schließt eine klinische Studienkollaboration mit Gilead Sciences ab; Ziel ist es, die Behandlungsergebnisse für Patientinnen und Patienten mit dreifach-negativem Brustkrebs zu verbessern, deren... ► Artikel lesen | |
| AURORA CANNABIS | 3,498 | -1,30 % | Curaleaf Holdings, Inc.: Curaleaf Challenges Aurora's Unilateral Rejection of Its Enhanced Proposal | STAMFORD, Conn., Oct. 19, 2026 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer... ► Artikel lesen | |
| CANOPY GROWTH | 0,597 | +1,19 % | Canopy Growth Corp (2): Canopy Growth to release fiscal Q2 results Nov. 6 | ||
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: STADA launches Virustad in Germany - based on Enzymatica's ColdZyme technology | STADA has launched the oral spray Virustad in the German pharmacy market. Virustad is built on Enzymatica's clinically documented ColdZyme® technology. The launch follows the partnership agreement signed... ► Artikel lesen | |
| ASTRAZENECA | 152,30 | -0,98 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| TILRAY BRANDS | 2,585 | -0,96 % | Tilray Brands, Inc.: West Ham United F.C. and BrewDog Unveil Boleyn Brew: A Fan-Created Matchday Beer Made by Hammers, for Hammers | ELLON, Scotland and LONDON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- BrewDog, a leader in U.K. craft beer and one of the world's most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 477,45 | +0,03 % | 115 Millionen US-Dollar mit einer Zelltherapie: Warum Mesoblast, Vertex und NurExone Zellen und Exosomen unterschiedlich nutzen | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| ZOETIS | 72,84 | -0,36 % | Zoetis: Was die FDA-Zulassung jetzt verändert | ||
| CRONOS GROUP | 3,034 | -1,24 % | Cronos Group Inc: Cronos Group completes CanAdelaar acquisition | ||
| DOCMORRIS | 17,030 | -0,29 % | DEUTSCHE BANK RESEARCH stuft DocMorris auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für DocMorris von 12,50 auf 17,50 Franken angehoben und die Einstufung auf "Buy" belassen. Die Online-Apotheke habe ihre Jahresziele... ► Artikel lesen |
Das Unternehmen VIVESTO AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,036 (+6,39 %) liegt der Kurs bei 0,599 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVESTO AB finden Sie auf Wallstreet Online.